Literature DB >> 28281292

Assessing global transitions in human development and colorectal cancer incidence.

Miranda M Fidler1, Freddie Bray1, Salvatore Vaccarella2, Isabelle Soerjomataram1.   

Abstract

Colorectal cancer incidence has paralleled increases in human development across most countries. Yet, marked decreases in incidence are now observed in countries that have attained very high human development. Thus, in this study, we explored the relationship between human development and colorectal cancer incidence, and in particular assessed whether national transitions to very high human development are linked to temporal patterns in colorectal cancer incidence. For these analyses, we utilized the Human Development Index (HDI) and annual incidence data from regional and national cancer registries. Truncated (30-74 years) age-standardized incidence rates were calculated. Yearly incidence rate ratios and HDI ratios, before and after transitioning to very high human development, were also estimated. Among the 29 countries investigated, colorectal cancer incidence was observed to decrease after reaching the very high human development threshold for 12 countries; decreases were also observed in a further five countries, but the age-standardized incidence rates remained higher than that observed at the threshold. Such declines or stabilizations are likely due to colorectal cancer screening in some populations, as well as varying levels of exposure to protective factors. In summary, it appears that there is a threshold at which human development predicts a stabilization or decline in colorectal cancer incidence, though this pattern was not observed for all countries assessed. Future cancer planning must consider the increasing colorectal cancer burden expected in countries transitioning towards higher levels of human development, as well as possible declines in incidence among countries reaching the highest development level.
© 2017 UICC.

Entities:  

Keywords:  cancer; colorectum; human development; incidence; international; socioeconomic

Mesh:

Year:  2017        PMID: 28281292     DOI: 10.1002/ijc.30686

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Measurement of Health-Related Quality of Life Among Colorectal Cancer Patients Using the Vietnamese Value Set of the EQ-5D-5L.

Authors:  Binh Thang Tran; Nhu Hiep Pham; Thanh Xuan Nguyen; Kui Son Choi; Dae Kyung Sohn; Sun-Young Kim; Jae Kyung Suh; Thuy Duyen Nguyen; Van Sang Phan; Dinh Trung Tran; The Thanh Nguyen; Thi Thanh Binh Nguyen; Minh Tu Nguyen; Jin-Kyoung Oh
Journal:  Patient Prefer Adherence       Date:  2020-12-04       Impact factor: 2.711

2.  The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors: 
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-10-21

3.  Inhibition of Ubiquitin Specific Protease 1 Sensitizes Colorectal Cancer Cells to DNA-Damaging Chemotherapeutics.

Authors:  Xin Xu; Shaoyan Li; Ximao Cui; Kunkun Han; Jun Wang; Xiaodan Hou; Long Cui; Songbing He; Jiecheng Xiao; Yili Yang
Journal:  Front Oncol       Date:  2019-12-18       Impact factor: 6.244

Review 4.  Deep Learning in Head and Neck Tumor Multiomics Diagnosis and Analysis: Review of the Literature.

Authors:  Xi Wang; Bin-Bin Li
Journal:  Front Genet       Date:  2021-02-10       Impact factor: 4.599

5.  Circular RNA CUL2 regulates the development of colorectal cancer by modulating apoptosis and autophagy via miR-208a-3p/PPP6C.

Authors:  Bin-Lin Yang; Guo-Qiang Liu; Ping Li; Xiao-Hui Li
Journal:  Aging (Albany NY)       Date:  2022-01-13       Impact factor: 5.682

Review 6.  Current State and Progress of Research on the Role of lncRNA in HBV-Related Liver Cancer.

Authors:  Xueke Wang; Meisong Kang; Chun Liu; Ting Lin; Xiao Han; Xiwen Jiang
Journal:  Front Cell Infect Microbiol       Date:  2021-11-18       Impact factor: 5.293

7.  DAB2IP decreases cell growth and migration and increases sensitivity to chemotherapeutic drugs in colorectal cancer.

Authors:  Guanting Wu; Xin Xu; Daiwei Wan; Diyuan Zhou; Yuan Feng; Junjie Chen; Zhijian Peng; Dong Fang; Xinyu Shi; Huihui Yao; Guoliang Chen; Liang Sun; Yizhou Yao; Guoqiang Zhou; Yili Yang; Songbing He
Journal:  Ann Transl Med       Date:  2021-08

8.  FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study.

Authors:  Priscilla de Albuquerque Ribeiro Gondinho; Paulo Goberlânio de Barros Silva; Mário Roberto Pontes Lisboa; Bruno Almeida Costa; Duílio Reis da Rocha Filho; Markus Andret Cavalcante Gifoni; Marcos Venicio Alves Lima; Roberto César Pereira Lima Junior; Mariana Lima Vale
Journal:  Int J Clin Oncol       Date:  2020-08-06       Impact factor: 3.402

9.  Antimalarial drug mefloquine inhibits nuclear factor kappa B signaling and induces apoptosis in colorectal cancer cells.

Authors:  Xin Xu; Jun Wang; Kunkun Han; Shaoyan Li; Feng Xu; Yili Yang
Journal:  Cancer Sci       Date:  2018-03-25       Impact factor: 6.716

10.  Geospatial analysis of the influence of family doctor on colorectal cancer screening adherence.

Authors:  Fabrizio Stracci; Alessio Gili; Giulia Naldini; Vincenza Gianfredi; Morena Malaspina; Basilio Passamonti; Fortunato Bianconi
Journal:  PLoS One       Date:  2019-10-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.